Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Evaluation of myo-inositol as a potential biomarker for depression in schizophrenia
GSH Redox Cycle vs
Comparative effectiveness research with established therapies would help determine the relative benefits and risks of these peptides compared to current standard treatments and would inform evidence-based treatment decisions
No European Medicines Agency (EMA) marketing authorisation exists for any of these three compounds
Data were generated and/or analysed by the Proteomics Resource Center (RRID: SCR_017797), Electron Microscopy Resource Center, Bioinformatics Resource Center, Fisher Drug Discovery Resource Center and the Flow Cytometry Resource Center at The Rockefeller University
24(5): p
US$ 28.18
US$ 27.83
US$ 25.20
